[go: up one dir, main page]

WO2000064422A3 - Novel treatment of neurotraumatic conditions with raf inhibitor - Google Patents

Novel treatment of neurotraumatic conditions with raf inhibitor Download PDF

Info

Publication number
WO2000064422A3
WO2000064422A3 PCT/EP2000/003730 EP0003730W WO0064422A3 WO 2000064422 A3 WO2000064422 A3 WO 2000064422A3 EP 0003730 W EP0003730 W EP 0003730W WO 0064422 A3 WO0064422 A3 WO 0064422A3
Authority
WO
WIPO (PCT)
Prior art keywords
raf inhibitor
novel treatment
neurotraumatic
conditions
neurotraumatic conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/003730
Other languages
French (fr)
Other versions
WO2000064422A2 (en
Inventor
Elaine Alison Irving
Andrew A Parsons
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9909650.5A external-priority patent/GB9909650D0/en
Priority claimed from GBGB9916655.5A external-priority patent/GB9916655D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to JP2000613413A priority Critical patent/JP2002542280A/en
Priority to AU45568/00A priority patent/AU4556800A/en
Priority to EP00927054A priority patent/EP1173254A2/en
Publication of WO2000064422A2 publication Critical patent/WO2000064422A2/en
Publication of WO2000064422A3 publication Critical patent/WO2000064422A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The use of Raf kinase inhibitors in the treatment of neurotraumatic diseases.
PCT/EP2000/003730 1999-04-27 2000-04-26 Novel treatment of neurotraumatic conditions with raf inhibitor Ceased WO2000064422A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2000613413A JP2002542280A (en) 1999-04-27 2000-04-26 New treatment
AU45568/00A AU4556800A (en) 1999-04-27 2000-04-26 Novel treatment
EP00927054A EP1173254A2 (en) 1999-04-27 2000-04-26 Novel treatment of neurotraumatic conditions with a raf inhibitor

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9909650.5A GB9909650D0 (en) 1999-04-27 1999-04-27 Novel treatment
GB9909650.5 1999-04-27
GB9916655.5 1999-07-15
GBGB9916655.5A GB9916655D0 (en) 1999-07-15 1999-07-15 Novel treatment

Publications (2)

Publication Number Publication Date
WO2000064422A2 WO2000064422A2 (en) 2000-11-02
WO2000064422A3 true WO2000064422A3 (en) 2001-03-01

Family

ID=26315478

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/003730 Ceased WO2000064422A2 (en) 1999-04-27 2000-04-26 Novel treatment of neurotraumatic conditions with raf inhibitor

Country Status (4)

Country Link
EP (1) EP1173254A2 (en)
JP (1) JP2002542280A (en)
AU (1) AU4556800A (en)
WO (1) WO2000064422A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7282500B2 (en) 2001-05-19 2007-10-16 Smithkline Beecham P.L.C. Imidazole-2-carboxamide derivatives as Raf kinase inhibitors

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL355912A1 (en) 1999-11-22 2004-05-31 Smithkline Beecham Plc. Novel compounds
GB0121488D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
WO2003022832A1 (en) * 2001-09-05 2003-03-20 Smithkline Beecham P.L.C. Pyridylfurans and pyrroles as raf kinase inhibitors
JP2006508051A (en) 2002-08-29 2006-03-09 サイオス インク． How to promote bone formation
US7244441B2 (en) 2003-09-25 2007-07-17 Scios, Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
WO2005123696A1 (en) * 2004-06-15 2005-12-29 Astrazeneca Ab Substituted quinazolones as anti-cancer agents
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991017156A1 (en) * 1990-05-10 1991-11-14 Pfizer Inc Neuroprotective indolone and related derivatives
WO1994015645A1 (en) * 1992-12-31 1994-07-21 Texas Biotechnology Corporation Antisense molecules directed against genes of the raf oncogene family
US5498610A (en) * 1992-11-06 1996-03-12 Pfizer Inc. Neuroprotective indolone and related derivatives
GB2306108A (en) * 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
WO1997035855A1 (en) * 1996-03-25 1997-10-02 Smithkline Beecham Corporation Novel treatment for cns injuries
WO1998022608A2 (en) * 1996-11-18 1998-05-28 Mcgill University Post-mitotic neurons containing adenovirus vectors that modulate apoptosis and growth
WO1999010325A1 (en) * 1997-08-06 1999-03-04 Glaxo Group Limited Benzylidene-1,3-dihydro-indol-2-one derivatives as receptor tyrosine kinase inhibitors, particularly of raf kinases
WO1999024404A1 (en) * 1997-11-07 1999-05-20 Amgen Inc. Substituted pyridine compounds as anti-inflammatory agents

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991017156A1 (en) * 1990-05-10 1991-11-14 Pfizer Inc Neuroprotective indolone and related derivatives
US5498610A (en) * 1992-11-06 1996-03-12 Pfizer Inc. Neuroprotective indolone and related derivatives
WO1994015645A1 (en) * 1992-12-31 1994-07-21 Texas Biotechnology Corporation Antisense molecules directed against genes of the raf oncogene family
GB2306108A (en) * 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
WO1997035855A1 (en) * 1996-03-25 1997-10-02 Smithkline Beecham Corporation Novel treatment for cns injuries
WO1998022608A2 (en) * 1996-11-18 1998-05-28 Mcgill University Post-mitotic neurons containing adenovirus vectors that modulate apoptosis and growth
WO1999010325A1 (en) * 1997-08-06 1999-03-04 Glaxo Group Limited Benzylidene-1,3-dihydro-indol-2-one derivatives as receptor tyrosine kinase inhibitors, particularly of raf kinases
WO1999024404A1 (en) * 1997-11-07 1999-05-20 Amgen Inc. Substituted pyridine compounds as anti-inflammatory agents

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7282500B2 (en) 2001-05-19 2007-10-16 Smithkline Beecham P.L.C. Imidazole-2-carboxamide derivatives as Raf kinase inhibitors

Also Published As

Publication number Publication date
JP2002542280A (en) 2002-12-10
WO2000064422A2 (en) 2000-11-02
AU4556800A (en) 2000-11-10
EP1173254A2 (en) 2002-01-23

Similar Documents

Publication Publication Date Title
AU2001259758A1 (en) Interleukin-1 inhibitors in the treatment of diseases
AP2004003161A0 (en) Substituted benzazoles and use thereof as raf kinase inhibitors.
IL164651A0 (en) Thiazolidinones and the use thereof as polo-like kinase inhibitors
MXPA03004794A (en) New mandelic acid derivatives and their use as throbin inhibitors.
MXPA03002814A (en) Morpholin-acetamide derivatives for the treatment of inflammatory diseases.
AU2003206785A1 (en) Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
AU2001244355A1 (en) Heterobiarylsulphonamides and their use as pde 7 inhibitors
AU2002248269A1 (en) Use of p38 inhibitors for the treatment of inflammation-enhanced cough
WO2002030353A3 (en) NF-λB INHIBITORS
AU3885900A (en) Inhibitors of the egf-receptor tyrosine kinase and their use
MXPA03003741A (en) Methods and compositions for the treatment of diseases of the eye.
WO2000064422A3 (en) Novel treatment of neurotraumatic conditions with raf inhibitor
AU2001228703A1 (en) Use of cox-2 inhibitors for the treatment of constipation
AU2001251306A1 (en) Treatment of sleep disorders with hypocretin-1
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
GC0000142A (en) An inhibitor of the formation of soluble human cd23.
AU2002210763A1 (en) Use of 1-ebio in the treatment of bipolar disorders
NO20043614L (en) 2'-halogen-3 ', 5'-dialkoxyphen-1'-yl-imino-2-imidazolidine in-derivatives and their use in the treatment of urinary incontinence
ZA200209632B (en) Methods for prevention of ulcers and improving physiological performance.
ZA966698B (en) Use of PDE inhibitors in the treatment of urinary bladder diseases.
AU2002256967A1 (en) Treating or reducing the risk of cardiovascular disease
AU2001275165A1 (en) Treatment of side effects associated with alcohol consumption
ZA200205415B (en) Novel therapeutic use of enoxaparin.
ZA200103250B (en) The treatment of immunomodulatory related and other diseases or conditions.
AU2002217081A1 (en) Sulfamidothienopyrimidines and the use of the same as phosphodiesterase V inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000927054

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2000 613413

Country of ref document: JP

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2000927054

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09980446

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000927054

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)